- Home
- RARE vs ITGR Comparison
RARE vs ITGR Comparison
Compare RARE & ITGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | ITGR |
|---|---|---|
| Founded | 2010 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 2014 | 2000 |
Fundamental Metrics
Financial Performance| Metric | RARE | ITGR |
|---|---|---|
| Price | $32.86 | $74.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 8 |
| Target Price | $85.20 | ★ $93.71 |
| AVG Volume (30 Days) | ★ 1.4M | 600.1K |
| Earning Date | 11-04-2025 | 10-23-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.42 |
| Revenue | $630,598,000.00 | ★ $1,831,074,000.00 |
| Revenue This Year | $19.09 | $9.58 |
| Revenue Next Year | $20.62 | N/A |
| P/E Ratio | ★ N/A | $30.48 |
| Revenue Growth | ★ 20.63 | 9.54 |
| 52 Week Low | $25.81 | $62.00 |
| 52 Week High | $46.75 | $146.36 |
Technical Indicators
Market Signals| Indicator | RARE | ITGR |
|---|---|---|
| Relative Strength Index (RSI) | 41.60 | 54.54 |
| Support Level | $35.65 | $72.17 |
| Resistance Level | $36.81 | $73.49 |
| Average True Range (ATR) | 1.49 | 1.63 |
| MACD | -0.23 | 1.03 |
| Stochastic Oscillator | 0.21 | 82.12 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About ITGR Integer Holdings Corporation
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.